8:30 am Registration & Coffee

The Evolution of Trastuzumab-Based Anti-HER2 ADC’s: Analysing the Latest Clinical Data

9:15 am Chair’s Opening Remarks – Exploring the Clinical Trials & Comparisons of the Current Trastuzumab-Based Anti-HER2 ADCs

9:30 am Disitamab Vedotin: A Novel HER2 ADC


– Disitamab vedotin is a HER2 ADC with an antibody designed to maximize drug delivery with higher affinity and internalization rate as compared to trastuzumab in preclinical models
– Exploring DV’s encouraging monotherapy clinical data across a range of HER2 expressing solid tumors
– Understanding how DV has demonstrated combination activity preclinically and clinically with anti-PD1

10:00 am Panel Discussion: The Evolution of Development & Use Beyond Breast Cancer

  • Reva Basho Assistant Professor, Breast Medical Oncology, Co-Director: Women’s Cancer Research Program, Cedars-Sinai Medical Center
  • Shane Olwill Chief Development Officer, Senior Vice President & Head of Translational Science, Pieris Pharmaceuticals
  • Aparna Parikh Assistant Professor & Director, Harvard Medical School & MGH Cancer Center's Global Cancer Care Program


• Sharing insights into future directions and what to anticipate as standards evolve for HER2 drugs in the clinic
• Addressing current treatment regimes and rational order of therapy
• Delving into combination thoughts and current status
• Understanding the current pitfalls in sequencing and selecting patients: how is HER2 high vs HER2 low
• Exploring potency, side effects, efficacy ratios and discussing how we can better connect pre-clinic to the clinic
• Overviewing the status of Gastric, CRC, Biliary, Bladder, NSCLC, CNS, paediatric and other relevant tumor indications
• Defining the conventional targeting and novel approaches in terms of efficacy and use

10:30 am Speed Networking

Overcoming the Challenges of Tumor Heterogeneity to Improve Patient Stratification

11:30 am Panel Discussion: The HER2 Expression Levels Debate: HER2 High vs HER2 Low

  • Funda Meric – Bernstam Chair, Department of Investigational Cancer Therapeutics & Medical Director, Institute for Personalized Cancer Therapy, MD Anderson Cancer Center
  • John Strickler Associate Professor of Medicine, Duke Clinical Research Institute
  • Jenny Karlsson Head of TRP Biochemistry, Bayer
  • Cecile Geuijen Chief Scientific Officer & Vice President - Oncology, Merus


• Progress towards an improved standard of HER2 expression definition
• Exploring the IHC & FISH standardization and improvement
• Understanding different requirements for expression measurement for various indications
• How does HER2 expression compare across indications?
• How does that compare for a therapeutic in terms of defining illegibility criteria?
• How to define non-HER2 positive?
• Standardizing the approach of measurement in the labs – addressing variation and variability between sample

12:00 pm Utilizing HER2 with Immune Agents: CAR-T Approach in Advanced Hematologic Cancers & Refractory Solid Tumors

  • Paul Rennert President & Chief Scientific Officer, Aleta Biotherapeutics


• Discussing patient selection and response biomarkers
• Challenges of clinical translation
• Latest data & future directions

12:30 pm Lunch

1:30 pm A Theranostic Approach to HER2 Radio-ADC Precision Medicine Using Affibody Scaffold Technology


• HER2-imaging is an attractive tool for characterization of tumor uptake
• High contrast tumor targeting ability demonstrated in patients with metastatic breast cancer
• Lack of tumor uptake in HER2 IHC+ tumor predicted lack of response to conventional HER2 treatment
• Imaging scaffold has been engineered to allow for molecular radiotherapy
• Preclinical molecular radiotherapy data supports clinical translation

2:00 pm The Uses of Precision Medicine for Patient Stratification


• Exploring cell-free DNA testing utility
• Advancements on detecting the heterogeneity of tumors
• Uses of liquid biopsy for metastatic disease and earlier detection
• Discussing implementation and strategy

2:30 pm Afternoon Refreshments & Poster Session

Unlocking the Hottest Preclinical Data & Combination Rationale for HER2 Clinical Progress

3:00 pm Progress in Anti-HER2 Agents & Combination

  • Wendy Hauck Global Associate Medical Director, Women’s Cancer Care, Eisai


• Understanding the line of therapy considerations
• Discussing the standard of care and how it differs between indications
• Chemo with antiengiogenics with immune therapy
• Latest results and directions
• Antiangeogenic and chemotherapy

3:30 pm Preclinical Progress: T-cell Engaging Bispecific Antibody Designed to Target Both HER2 on Cancer Cells & CD3 on T-Cells

  • Teemu Junttila Senior Principal Scientist - Technology & Translational Oncology, Genentech


• Challenges and promise in redirecting T cells to the tumor site
• Latest data and future directions

4:00 pm Combining Targeted Agents with Checkpoint Inhibitors


• Delving into PD-L1 combination studies
• Understanding rationale depending on drug pathology
• Clinical data comparisons
• Relevance to treatment regimes and study design

4:30 pm Chair’s Closing Remarks & End of Conference Day One